Parkinson's disease cognitive network correlates with caudate dopamine

NeuroImage

Volumn 78, Issue , 2013, Pages 204-209

  Niethammer, Martin ^a   Tang, Chris C ^a   Ma, Yilong ^a   Mattis, Paul J ^a   Ko, Ji Hyun ^a   Dhawan, Vijay ^a   Eidelberg, David ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Caudate; Cognition; Dopamine; Parkinson's disease

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BRAIN MAPPING; BRAIN NERVE CELL; CAUDATE NUCLEUS; CEREBELLUM; CLINICAL ARTICLE; COGNITION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE DURATION; DOPAMINERGIC SYSTEM; HUMAN; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PARKINSON DISEASE; PRECUNEUS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

CAUDATE NUCLEUS; DOPAMINE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TROPANES;

EID: 84877325015     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2013.03.070     Document Type: Article

References (44)

1. Aarsland D., Kurz M.W. The epidemiology of dementia associated with Parkinson disease. J. Neurol. Sci. 2010, 289:18-22.
2. Alves G., Larsen J.P., Emre M., Wentzel-Larsen T., Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov. Disord. 2006, 21:1123-1130.
3. Bohnen N.I., Kaufer D.I., Ivanco L.S., Lopresti B., Koeppe R.A., Davis J.G., Mathis C.A., Moore R.Y., DeKosky S.T. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch. Neurol. 2003, 60:1745-1748.
4. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
5. 18F]fluoro-l-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiol. Aging 2005, 26:891-898.
6. Carbon M., Ma Y., Barnes A., Dhawan V., Chaly T., Ghilardi M.F., Eidelberg D. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in parkinsonism. NeuroImage 2004, 21:1497-1507.
7. 18F-dopa PET in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2005, 76:1204-1210.
8. Cools R. Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson's disease. Neurosci. Biobehav. Rev. 2006, 30:1-23.
9. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci. 2009, 32:548-557.
10. Ekman U., Eriksson J., Forsgren L., Mo S.J., Riklund K., Nyberg L. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: a cross-sectional study. Lancet Neurol. 2012, 11:679-687.
11. Emre M., Aarsland D., Albanese A., Byrne E.J., Deuschl G., De Deyn P.P., Durif F., Kulisevsky J., van Laar T., Lees A., Poewe W., Robillard A., Rosa M.M., Wolters E., Quarg P., Tekin S., Lane R. Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 2004, 351:2509-2518.
12. Gotham A.M., Brown R.G., Marsden C.D. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain 1988, 111(Pt 2):299-321.
13. Green J., McDonald W.M., Vitek J.L., Evatt M., Freeman A., Haber M., Bakay R.A., Triche S., Sirockman B., DeLong M.R. Cognitive impairments in advanced PD without dementia. Neurology 2002, 59:1320-1324.
14. Hilker R., Thomas A.V., Klein J.C., Weisenbach S., Kalbe E., Burghaus L., Jacobs A.H., Herholz K., Heiss W.D. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005, 65:1716-1722.
15. Hirano S., Dhawan V., Eidelberg D. PET imaging in movement disorders. Encyclopedia of Movement Disorders 2010, 452-461. Academic Press, New York. K. Kompoliti, L. Verhagen (Eds.).
16. Hirano S., Shinotoh H., Eidelberg D. Functional brain imaging of cognitive dysfunction in Parkinson's Disease. J. Neurol. Neurosurg. Psychiatry 2012, 83:963-969.
17. Hosokai Y., Nishio Y., Hirayama K., Takeda A., Ishioka T., Sawada Y., Suzuki K., Itoyama Y., Takahashi S., Fukuda H., Mori E. Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov. Disord. 2009, 24:854-862.
18. Huang C., Mattis P., Tang C., Perrine K., Carbon M., Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson's disease. NeuroImage 2007, 34:714-723.
19. Huang C., Tang C., Feigin A., Lesser M., Ma Y., Pourfar M., Dhawan V., Eidelberg D. Changes in network activity with the progression of Parkinson's disease. Brain 2007, 130:1834-1846.
20. Huang C., Mattis P., Perrine K., Brown N., Dhawan V., Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008, 70:1470-1477.
21. Hughes A., Daniel S., Kilford L., Lees A. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992, 55:181-184.
22. 18F]fluoro-l-dopa PET study. Brain 2002, 125:1358-1365.
23. Jacobson N.S., Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J. Consult. Clin. Psychol. 1991, 59:12-19.
24. Janvin C.C., Aarsland D., Larsen J.P. Cognitive predictors of dementia in Parkinson's disease: a community-based, 4-year longitudinal study. J. Geriatr. Psychiatry Neurol. 2005, 18:149-154.
25. Jokinen P., Bruck A., Aalto S., Forsback S., Parkkola R., Rinne J.O. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat. Disord. 2009, 15:88-93.
26. Kriegeskorte N., Simmons W.K., Bellgowan P.S., Baker C.I. Circular analysis in systems neuroscience: the dangers of double dipping. Nat. Neurosci. 2009, 12:535-540.
27. Kriegeskorte N., Lindquist M.A., Nichols T.E., Poldrack R.A., Vul E. Everything you never wanted to know about circular analysis, but were afraid to ask. J. Cereb. Blood Flow Metab. 2010, 30:1551-1557.
28. Looi J.C., Lindberg O., Zandbelt B.B., Ostberg P., Andersen C., Botes L., Svensson L., Wahlund L.O. Caudate nucleus volumes in frontotemporal lobar degeneration: differential atrophy in subtypes. AJNR Am. J. Neuroradiol. 2008, 29:1537-1543.
29. 18F]FPCIT binding in early stage Parkinson's disease: a PET study. Synapse 2002, 45:125-133.
30. Ma Y., Tang C., Spetsieris P., Dhawan V., Eidelberg D. Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J. Cereb. Blood Flow Metab. 2007, 27:597-605.
31. Maassen G.H. The standard error in the Jacobson and Truax Reliable Change Index: the classical approach to the assessment of reliable change. J. Int. Neuropsychol. Soc. 2004, 10:888-893.
32. Mattis P.J., Tang C.C., Ma Y., Dhawan V., Eidelberg D. Network correlates of the cognitive response to levodopa in Parkinson disease. Neurology 2011, 77:858-865.
33. Muller U., Wachter T., Barthel H., Reuter M., von Cramon D.Y. Striatal [123I]beta-CIT SPECT and prefrontal cognitive functions in Parkinson's disease. J. Neural Transm. 2000, 107:303-319.
34. Niethammer M., Eidelberg D. Metabolic brain networks in translational neurology: concepts and applications. Ann. Neurol. 2012, 72:635-647.
35. O'Brien J.T., Colloby S., Fenwick J., Williams E.D., Firbank M., Burn D., Aarsland D., McKeith I.G. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch. Neurol. 2004, 61:919-925.
36. Pappata S., Santangelo G., Aarsland D., Vicidomini C., Longo K., Bronnick K., Amboni M., Erro R., Vitale C., Caprio M.G., Pellecchia M.T., Brunetti A., De Michele G., Salvatore M., Barone P. Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. Neurology 2011, 77:1357-1362.
37. Polito C., Berti V., Ramat S., Vanzi E., De Cristofaro M.T., Pellicano G., Mungai F., Marini P., Formiconi A.R., Sorbi S., Pupi A. Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease. Neurobiol. Aging 2012, 33(206):e229-e239.
38. Ribeiro M.J., Vidailhet M., Loc'h C., Dupel C., Nguyen J.P., Ponchant M., Dolle F., Peschanski M., Hantraye P., Cesaro P., Samson Y., Remy P. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch. Neurol. 2002, 59:580-586.
39. 18F]fluorodopa positron emission tomographic study. Arch. Neurol. 2000, 57:470-475.
40. Spetsieris P.G., Eidelberg D. Scaled subprofile modeling of resting state imaging data in Parkinson's disease: methodological issues. NeuroImage 2011, 54:2899-2914.
41. Tang C., Poston K., Dhawan V., Eidelberg D. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J. Neurosci. 2010, 30:1049-1056.
42. Thobois S., Jahanshahi M., Pinto S., Frackowiak R., Limousin-Dowsey P. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences. NeuroImage 2004, 23:1-16.
43. van Beilen M., Portman A.T., Kiers H.A., Maguire R.P., Kaasinen V., Koning M., Pruim J., Leenders K.L. Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: a clinical and FDOPA-PET study. Parkinsonism Relat. Disord. 2008, 14:224-228.
44. Vul E., Harris C., Winkielman P., Pashler H. Puzzlingly high correlations in fMRI studies of emotion, personality, and social cognition. Perspect. Psychol. Sci. 2009, 4:274-290.